Lantern Pharma Inc (LTRN) Stock Price, Quote & News

Company Profile

Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 277 1136

Website: www.lanternpharma.com

Address:

1920 McKinney Avenue, 7th Floor, Dallas, United States

NetworkNewsWire Jul. 16 at 4:32 PM

BioMedNewsBreaks — $LTRN Taps IBN to Lead Corporate Communications Amid AI-Driven Oncology Pipeline Progress https://ibn.fm/4jRwm

0 · Reply

sn0wball Jul. 15 at 7:03 PM

$LTRN sad stock, reminds of the beloved cat i lost in dec. RIP

0 · Reply

BearTamerTrading Jul. 15 at 6:47 PM

$LTRN If you guys would stop selling for less and remove the low sale orders she would fly, just saying 😂.

0 · Reply

NetworkNewsWire Jul. 15 at 6:26 PM

BioMedNewsBreaks – $LTRN Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies https://ibn.fm/AUDcf

0 · Reply

CaliforniaBikers Jul. 15 at 6:25 PM

$LTRN a-i news

0 · Reply

sn0wball Jul. 15 at 6:02 PM

$LTRN rising nice MoneyHero Limited (MNY)

0 · Reply

sn0wball Jul. 15 at 3:42 PM

$LTRN 2 hours ago is this go boom? Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

0 · Reply

BearTamerTrading Jul. 15 at 2:58 PM

$LTRN Hoping for a good push from these levels. Time will tell us all.

0 · Reply

Boxerman Jul. 15 at 1:53 PM

$LTRN .10 spread no thanks

0 · Reply

Slapshot22 Jul. 15 at 1:50 PM

$LTRN Now up on the LTRN web site as well: https://ir.lanternpharma.com/news-1/news/news-details/2025/Lantern-Pharma-Unveils-Groundbreaking-AI-Powered-Module-to-Predict-Activity-and-Efficacy-of-Combination-Regimens-in-Clinical-Cancer-Treatment/default.aspx

0 · Reply

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

Jun 16, 2025, 8:30 AM EDT - 4 weeks ago

Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

May 29, 2025, 8:30 AM EDT - 6 weeks ago

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

May 15, 2025, 3:04 PM EDT - 2 months ago

Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript

May 15, 2025, 8:45 AM EDT - 2 months ago

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

May 12, 2025, 9:00 AM EDT - 2 months ago

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

May 8, 2025, 8:30 AM EDT - 2 months ago

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

May 5, 2025, 8:55 AM EDT - 2 months ago

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

Mar 27, 2025, 8:35 PM EDT - 3 months ago

Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:01 PM EDT - 3 months ago

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Mar 20, 2025, 8:00 AM EDT - 4 months ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

Feb 19, 2025, 8:00 AM EST - 5 months ago

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Jan 27, 2025, 7:55 AM EST - 6 months ago

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Dec 9, 2024, 8:15 AM EST - 7 months ago

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Dec 3, 2024, 8:00 AM EST - 8 months ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Nov 26, 2024, 8:45 AM EST - 8 months ago

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Nov 19, 2024, 8:00 AM EST - 8 months ago

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Nov 8, 2024, 7:23 PM EST - 8 months ago

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 8 months ago

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Nov 5, 2024, 8:00 AM EST - 9 months ago

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Oct 31, 2024, 8:00 AM EDT - 9 months ago

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Oct 23, 2024, 8:45 AM EDT - 9 months ago

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Oct 21, 2024, 8:00 AM EDT - 9 months ago

Lantern Pharma to Host & Participate in Two Public Webinars During October

Oct 15, 2024, 9:07 AM EDT - 9 months ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Sep 23, 2024, 8:00 AM EDT - 10 months ago

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers

Aug 10, 2024, 4:01 AM EDT - 1 year ago

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Aug 7, 2024, 9:31 AM EDT - 1 year ago

Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

Jul 10, 2024, 8:30 AM EDT - 1 year ago

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Jun 12, 2024, 7:30 AM EDT - 1 year ago

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

May 9, 2024, 4:02 PM EDT - 1 year ago

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

May 6, 2024, 3:00 AM EDT - 1 year ago

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

May 2, 2024, 7:30 AM EDT - 1 year ago

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

Apr 24, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Apr 22, 2024, 8:12 AM EDT - 1 year ago

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Mar 18, 2024, 11:14 PM EDT - 1 year ago

Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript

Mar 18, 2024, 4:02 PM EDT - 1 year ago

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Mar 11, 2024, 7:30 AM EDT - 1 year ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

Mar 5, 2024, 8:01 AM EST - 1 year ago

Lantern To Participate in H.C Wainwright & Co.'s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Mar 4, 2024, 8:01 AM EST - 1 year ago

Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

Feb 15, 2024, 8:01 AM EST - 1 year ago

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

Jan 17, 2024, 7:30 AM EST - 1 year ago

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

Nov 30, 2023, 8:00 AM EST - 1 year ago

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

Nov 9, 2023, 5:28 AM EST - 1 year ago

Lantern Pharma Inc. (LTRN) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 4:01 PM EST - 1 year ago

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights

Nov 1, 2023, 8:00 AM EDT - 1 year ago

Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET

Oct 10, 2023, 8:00 AM EDT - 1 year ago

Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET

NetworkNewsWire Jul. 16 at 4:32 PM

BioMedNewsBreaks — $LTRN Taps IBN to Lead Corporate Communications Amid AI-Driven Oncology Pipeline Progress https://ibn.fm/4jRwm

0 · Reply

sn0wball Jul. 15 at 7:03 PM

$LTRN sad stock, reminds of the beloved cat i lost in dec. RIP

0 · Reply

BearTamerTrading Jul. 15 at 6:47 PM

$LTRN If you guys would stop selling for less and remove the low sale orders she would fly, just saying 😂.

0 · Reply

NetworkNewsWire Jul. 15 at 6:26 PM

BioMedNewsBreaks – $LTRN Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies https://ibn.fm/AUDcf

0 · Reply

CaliforniaBikers Jul. 15 at 6:25 PM

$LTRN a-i news

0 · Reply

sn0wball Jul. 15 at 6:02 PM

$LTRN rising nice MoneyHero Limited (MNY)

0 · Reply

sn0wball Jul. 15 at 3:42 PM

$LTRN 2 hours ago is this go boom? Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

0 · Reply

BearTamerTrading Jul. 15 at 2:58 PM

$LTRN Hoping for a good push from these levels. Time will tell us all.

0 · Reply

Boxerman Jul. 15 at 1:53 PM

$LTRN .10 spread no thanks

0 · Reply

Slapshot22 Jul. 15 at 1:50 PM

0 · Reply

Slapshot22 Jul. 15 at 1:48 PM

$LTRN News reported a few minutes ago: More AI RADR activity Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment 07/15/2025 - 09:40 AM The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern’s AI platform, RADR ®, and will initially focus on tailored combinations of DNA damaging agents and DNA repair inhibitors Addresses $50+ billion combination cancer therapy market projected to grow 8.5% annually through 2030 Over 60% of cancer patients received DNA damaging agents or DNA repair inhibitors as part of their clinical treatment and unique AI-powered module will focus on predicting the efficacy, safety and biomarker signatures associated with those potential treatments Platform successfully guided FDA-cleared Phase 1B/2 trial design for LP-184 + olaparib in triple-negative breast cancer https://www.stocktitan.net/news/LTRN/lantern-pharma-unveils-groundbreaking-ai-powered-module-to-predict-hdrqtu6n4e96.html

0 · Reply

mankind1 Jul. 10 at 7:33 PM

$LTRN this will probably drop again 3, if there is no news to maintain it's price.

1 · Reply

MGeronimo Jul. 9 at 11:05 PM

$LTRN IN AT 3.27 on drug patent news

0 · Reply

TopAlrt Jul. 9 at 12:13 PM

$LTRN $LFWD at 0.79 Float: na | Short: 2.9 % Rel. Vol.: 33.6x | Vol.: 13.2K $ News: MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion 2025-07-09 08:01:45

0 · Reply

ManuelFromGermany Jul. 9 at 9:24 AM

$LTRN thanks for the 4,40$ pre Markt

0 · Reply

mankind1 Jul. 8 at 10:19 PM

$LTRN hmm anyone know why this popped? It does that from time to time

0 · Reply

ManuelFromGermany Jul. 8 at 6:07 PM

$BTCS $LTRN Pre-market the point went off here top 4.70 $ here we will run again today or tonight do not be naive buy before it is too late🚀

0 · Reply

ManuelFromGermany Jul. 8 at 5:52 PM

$LTRN Pre-market the point went off here top 4.70 $ here we will run again today or tonight do not be naive buy before it is too late

0 · Reply

_www_larval_com_ Jul. 8 at 4:12 PM

$LTRN just turned -3% lower to 13% (~3Mv) moments ago, 07/18 options, follow for more volatility.

0 · Reply

Drugtrade Jul. 8 at 3:59 PM

$LTRN been long here since jan, down a bit yet slightly optimisitc. Concerned about cash level no idea as to short term price target

0 · Reply

BigSqueezeComing Jul. 8 at 2:03 PM

$LTRN PT 3.8+

0 · Reply

Hunnel Jul. 8 at 12:18 PM

$LTRN something is brewing like I said last night

0 · Reply

Market Cap	43.03M
Revenue (ttm)	0.00
Net Income (ttm)	-20.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	159,300
Avg Vol	160,016
Day's Range	N/A - N/A
Shares Out	10.79M
Stochastic %K	47%
Beta	1.54
Analysts	Strong Sell
Price Target	$25.50